You are herePharma News
Head and neck cancers affect nearly 50,000 people in the United States each year. The main risk factors include alcohol, smoking and human papillomavirus (HPV), a common sexually transmitted infection that often goes undetected. Researchers at Johns Hopkins University have developed a new test that uses blood and saliva to detect head and neck cancers. The research is published in Science Translational Medicine.
(NewsVoir); 1mg.com, India’s leading m-health platform, today launched ‘Doctors by 1mg’ on the Android platform, to help Delhi NCR discover best doctors and book appointments. A companion to the 1mg App which is the leading consumer health platform with over 3 M downloads, the new launch demonstrates company’s commitment towards building a platform that will aid users in managing their health effectively.
Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia. The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.
TAKE Solutions Ltd., a global business technology solutions provider, was awarded a patent by the United States Patent and Trademark Office (USPTO) for its "Method for Optimizing Clinical Data Standardization". It provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods. TAKE’s global headquarters is in Chennai, India; its US headquarters is located in Princeton, New Jersey. This process leverages TAKE Solutions’ clinical accelerators to reduce the time taken to standardize trial data by over 50% (when compared to standardization without the accelerators), thus reducing time to market.
Maruishi Pharmaceutical Co., Ltd. & Daiichi Sankyo Company, Limited, a global pharmaceutical company Collaborate to commercialize the general anaesthesia analgesic, remifentanil injection generic. Maruishi Pharmaceutical is currently applying for a manufacture and marketing license. Once Maruishi Pharmaceutical has acquired a license for the manufacturing and marketing of this drug, the plan is for Maruishi Pharmaceutical to handle its manufacture and Daiichi Sankyo to handle its marketing, while both companies will jointly conduct promotion activities.
A drug helpful in treating high blood pressure is now effective in ceasing cocaine and alcohol addiction in animal models. This new research give hopes to millions of addicts around the world. Anti-hypertensive drugs block a particular type of ion channel, which is expressed not only in heart and blood vessels but also in certain brain cells. The researchers found that blocking these ion channels in brain cells, using a drug called isradipine, appears to reverse the rewiring that underlies memories of addiction-associated places. The research is published in the Molecular Psychiatry.
Researchers have developed a new test that can detect every known human virus that currently or previously infected a person from a single drop of blood. The method developed by Howard Hughes Medical Institute (HHMI) researchers can test for current and past infections with any known human virus, including HIV and hepatitis C.
Zydus Cadila, a global pharmaceutical company, has received the final approval from the US Food and Drug Administration (FDA) to market pyridostigmine bromide tablets USP, 60 mg. It is used for treating various neurological disorders.
The United States Food and Drug Administration has approved Impax Specialty Pharma's Zomig Nasal Spray for treatment of acute migraine with or without aura in pediatric patients who are 12 years and older.
Vitiligo is a common, psychologically devastating condition that causes skin to lose its pigmentation or color. Current treatments, such as steroid creams and light therapy, are not reliably effective in reversing the disease. A new study says, a drug used for treating rheumatoid arthritis has restored skin color in a female patient suffering from vitiligo -- a common, skin condition where portion of skin loses its pigmentation or color. The report was published in JAMA Dermatology.